U.S., May 3 -- ClinicalTrials.gov registry received information related to the study (NCT06955325) titled 'Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations' on April 16.
Brief Summary: This study explores how adjuvant therapy affects survival in completely resected high-risk stage IA-IB NSCLC patients with different driver gene mutations.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
DRUG: Icotinib
Oral icotinib tablets (125 mg) administered three times daily (TID) for up to 1 year or until disease recurrence or unacceptable toxicity. Icotinib is an EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing mut...